fundamentals sub menu Fundamentals Year None20202019201820172016 Sorrento and Celularity to Initiate Emergency Allogeneic Natural Killer (NK) Cell Therapy Development for Coronavirus Infection Jan 29, 2020 Sorrento Board Rejects Latest Acquisition Proposal Jan 27, 2020 Sorrento to Present Late Breaking Positive Clinical Trial Data for Resiniferatoxin at Two Prestigious Upcoming Pain Conferences Jan 27, 2020 Sorrento Therapeutics, Inc. Received Non-Binding Acquisition Proposal Jan 10, 2020 Sorrento Announces Filing for Approval of Infliximab Biobetter Antibody by Its Partner Mabpharm in China Jan 06, 2020 Tools Print Page Email Alerts RSS Feeds Email Page
Year None20202019201820172016 Sorrento and Celularity to Initiate Emergency Allogeneic Natural Killer (NK) Cell Therapy Development for Coronavirus Infection Jan 29, 2020 Sorrento Board Rejects Latest Acquisition Proposal Jan 27, 2020 Sorrento to Present Late Breaking Positive Clinical Trial Data for Resiniferatoxin at Two Prestigious Upcoming Pain Conferences Jan 27, 2020 Sorrento Therapeutics, Inc. Received Non-Binding Acquisition Proposal Jan 10, 2020 Sorrento Announces Filing for Approval of Infliximab Biobetter Antibody by Its Partner Mabpharm in China Jan 06, 2020
Sorrento and Celularity to Initiate Emergency Allogeneic Natural Killer (NK) Cell Therapy Development for Coronavirus Infection Jan 29, 2020
Sorrento to Present Late Breaking Positive Clinical Trial Data for Resiniferatoxin at Two Prestigious Upcoming Pain Conferences Jan 27, 2020
Sorrento Announces Filing for Approval of Infliximab Biobetter Antibody by Its Partner Mabpharm in China Jan 06, 2020